Update shared on04 Sep 2025
Analysts remain bullish on Insulet due to accelerating revenue growth, increased guidance, and strong international momentum—particularly from Omnipod and favorable reimbursement trends—offsetting sector regulatory concerns, resulting in an unchanged consensus price target of $353.39.
Analyst Commentary
- Bullish analysts cite Insulet's Q2 results showing reaccelerated growth, with revenue and earnings surpassing estimates and driving market share gains, especially among MDI conversions.
- The company raised its full-year guidance confidently, expecting continued strength across all geographic markets and customer segments.
- Reimbursement trends favoring pay-as-you-go economics and increasing prescriber and patient preference for Omnipod are seen as unique competitive advantages.
- International sales momentum is highlighted as a particularly strong and underappreciated growth driver.
- Sector-wide concerns linger about potential Medicare reforms and competitive bidding proposals, but analysts generally view fears of significant impact from these regulatory changes as overblown, pointing to stable macro factors such as calm inflation, market highs, and favorable foreign exchange.
What's in the News
- Insulet raised its full-year 2025 revenue guidance, now expecting constant currency Total Omnipod growth of 25%-28% (up from 20%-23%) and Total revenue growth of 24%-27% (up from 19%-22%) (Key Developments).
- Third-quarter 2025 guidance projects constant currency Total Omnipod revenue growth of 24%-27% and total revenue growth of 22%-25% (Key Developments).
- Insulet completed a share repurchase of 93,032 shares worth $30.09 million between April and June 2025, representing 0.13% of shares outstanding, under the buyback program announced in May 2025 (Key Developments).
- The Omnipod 5 app for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring System, enhancing diabetes management through full mobile control and automated insulin delivery; available on the U.S. Apple App Store (Key Developments).
- Shares of Insulet and other diabetes device makers rallied after RFK announced plans for a major HHS campaign to promote wearable health devices like CGMs across the U.S. (Pink Sheet/Periodicals).
Valuation Changes
Summary of Valuation Changes for Insulet
- The Consensus Analyst Price Target remained effectively unchanged, at $353.39.
- The Discount Rate for Insulet remained effectively unchanged, at 7.59%.
- The Consensus Revenue Growth forecasts for Insulet remained effectively unchanged, at 17.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.